Glanbia plc (LON:GLB)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 4.79B +78.2% |
| Revenue (ttm) | 3.07B +3.8% |
| Net Income | 178.00M +96.8% |
| EPS | 0.72 +108.0% |
| Shares Out | n/a |
| PE Ratio | 26.89 |
| Forward PE | 16.57 |
| Dividend | 0.37 (1.80%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 30,458 |
| Open | 23.60 |
| Previous Close | 24.20 |
| Day's Range | 23.00 - 24.20 |
| 52-Week Range | 11.90 - 25.60 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Glanbia
Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing business; property and land dealing business; property leasing; provision of business services a... [Read more]
Financial Performance
In fiscal year 2025, Glanbia's revenue was $3.95 billion, an increase of 2.78% compared to the previous year's $3.84 billion. Earnings were $183.30 million, an increase of 11.29%.
Financial numbers in USD Financial StatementsNews
Glanbia hikes profit forecast as weight-loss drugs boost demand for protein products
Nutrition supplement maker Glanbia hiked its full-year profit forecast on Thursday following bumper demand for its protein products, including from customers using them in tandem with weight-loss dru...
Glanbia Earnings Call Transcript: H1 2026
Strong H1 2026 results featured 30% EPS growth and 7% revenue growth, driven by robust demand and margin expansion across all segments. Upgraded full-year guidance reflects continued momentum, with strategic investments and transformation savings supporting future growth.
Glanbia Quarterly report: H1 2026
Glanbia has published its H1 2026 quarterly earnings report on August 6, 2026.
Glanbia Slides: H1 2026
Glanbia has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 6, 2026.
Glanbia Earnings Call Transcript: Q1 2026
Group revenue rose 7.2% like-for-like, led by double-digit growth in Performance Nutrition and Health & Nutrition. Adjusted EPS is now expected at the upper end of guidance, with strong demand, price increases, and efficiency gains offsetting input cost pressures.
Glanbia Slides: Q1 2026
Glanbia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Glanbia Earnings release: Q1 2026
Glanbia released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Glanbia Earnings Call Transcript: H2 2025
Robust 2025 performance with revenue and volume growth across all segments, despite margin pressure from elevated whey costs. Strategic transformation, portfolio optimization, and capacity expansion underpin medium-term growth targets, with strong cash flow and shareholder returns.
Glanbia Annual report: H2 2025
Glanbia has published its H2 2025 annual report on February 25, 2026.
Glanbia Annual report: H2 2025
Glanbia has published its H2 2025 annual report on February 25, 2026.
Glanbia Slides: H2 2025
Glanbia has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 25, 2026.
Glanbia Transcript: CMD 2025
Sharpened focus on performance and health nutrition drives ambitious growth targets, with innovation, global expansion, and operational efficiency at the core. Financial guidance includes 5%-7% annual organic revenue growth in performance nutrition, 4%-6% in health & nutrition, and a raised dividend payout ratio.
Glanbia Slides: FY 2025
Glanbia has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 19, 2025.
Glanbia Earnings Call Transcript: Q3 2025
Revenue grew 3.3% year-to-date, driven by strong demand in performance nutrition, health and nutrition, and dairy segments. Upgraded full-year guidance reflects robust volume growth, successful innovation, and portfolio optimization, with adjusted EPS now expected at the upper end of $1.30-$1.33.
Glanbia Earnings release: Q3 2025
Glanbia released its Q3 2025 earnings on November 5, 2025, summarizing the period's financial results.
Glanbia Slides: Q3 2025
Glanbia has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 5, 2025.
Glanbia to sell Slimfast US to Heartland Food Products group of US
Irish-based nutrition supplement maker Glanbia on Wednesday said it had agreed to sell its weight management brand SlimFast US to Heartland Food Products Group for an undisclosed sum.
Glanbia Earnings Call Transcript: H1 2025
H1 2025 saw resilient results with revenue up 6% and strong Health & Nutrition and Dairy Nutrition growth, offset by Performance Nutrition declines. Upgraded full-year EPS guidance reflects improved trends, while strategic divestments and acquisitions support future growth.
Glanbia Quarterly report: H1 2025
Glanbia has published its H1 2025 quarterly earnings report on August 13, 2025.
Glanbia Slides: H1 2025
Glanbia has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 13, 2025.
Flax Protein Markets and Companies Analysis Report 2025 with Forecasts to 2029 & 2034 - Featuring Glanbia Nutritionals, Grain Millers, Myprotein, Linwoods Health Foods, Bioriginal Food & Science Corp. and More
Explore the booming Flax Protein Market: projected to soar from $38.54B in 2024 to $56.42B by 2029, driven by the rise in plant-based diets and demand for minimally processed foods. Explore the boomin...
Glanbia shares jump after 'better than feared' first quarter
Shares in nutrition supplement maker Glanbia jumped 10% on Wednesday after analysts pointed to a "better than feared" first quarter performance that allowed the Irish group to maintain its full year e...
Supplements producer Glanbia's shares dive on profit warning
Shares in nutrition supplement maker Glanbia slid by 15% on Wednesday after it warned that it expects earnings to fall by up to 11% this year, hit by a longer than expected rise in the cost of whey, a...